Medical Cannabis Prescription UK: Who Qualifies, Costs, Legal Rights and Driving Rules

For anyone considering a medical cannabis prescription UK route, the first reality check is that it is neither a retail purchase nor a shortcut around cannabis law. It is a clinician-led treatment decision, usually made through a private specialist clinic, with a prescription for a named patient and a specific product.

Cannabis-based products for medicinal use have been legal to prescribe in the UK since November 2018. Yet access remains limited, particularly on the NHS, and the route can be costly. The practical question is not simply whether cannabis might help a condition. It is whether a specialist considers it appropriate after reviewing the diagnosis, previous treatment, potential benefit, side effects and wider risks.

Who can get a medical cannabis prescription in the UK?

There is no single statutory checklist that automatically entitles somebody to a prescription. A diagnosis alone is not enough, and neither is prior cannabis use. Prescribing decisions are individual clinical judgements.

In practice, private clinics commonly assess adults with long-term conditions where standard care has not delivered adequate relief or has caused unacceptable adverse effects. Chronic pain, anxiety disorders, post-traumatic stress disorder, migraine, neurological conditions and symptoms associated with cancer care are among the reasons patients may seek an assessment. That does not mean cannabis is clinically suitable, or supported by equally strong evidence, for each of those conditions.

Many clinics ask patients to have tried two conventional treatments relevant to their condition before booking an appointment. This is a common clinic policy rather than a universal legal rule. The evidence needed may include a GP summary of care record, clinic letters, medication history and evidence of the diagnosis. Some services will request additional information from a GP or treating consultant.

A prescribing doctor must be a specialist doctor listed on the General Medical Council Specialist Register. A GP cannot ordinarily start a prescription for an unlicensed cannabis-based product independently, although GPs may remain involved in a patient's wider care. This distinction matters when websites imply that a simple online questionnaire can result in legal medical cannabis.

Conditions, evidence and clinical caution

The strongest UK evidence base is not evenly spread across medical cannabis. Certain licensed cannabis-derived medicines have specific authorised uses: Epidyolex for particular rare epilepsies, Sativex for moderate to severe spasticity in multiple sclerosis, and nabilone for chemotherapy-induced nausea and vomiting when other anti-sickness treatments have not worked.

By contrast, much of the private prescription market involves unlicensed cannabis-based products. These may include oils, capsules or dried flower intended for use in a medical vaporiser. An unlicensed product is not inherently illegal or poor quality. It means it has not received a marketing authorisation for that particular indication in the way a conventional licensed medicine has.

That status should prompt informed questions rather than alarm. The prescriber should explain why they believe the potential benefits outweigh the risks, what evidence informs the decision, and what alternatives remain available. They should also discuss uncertainty. For several commonly cited conditions, patient-reported improvements and observational studies exist, but high-quality randomised trial evidence is more limited than public discussion can suggest.

How the private prescription process usually works

The route is fairly structured, even where much of it is completed remotely. Patients usually submit medical records and complete an initial screening form. If the clinic considers the referral potentially appropriate, it arranges a consultation with a specialist.

The clinician should ask about the condition itself, current and previous medicines, mental health history, sleep, alcohol and drug use, pregnancy or plans for pregnancy, work, driving and any history of cardiovascular illness. A family or personal history of psychosis can be particularly relevant, because THC-containing products may not be appropriate for some people at higher risk.

If a prescription is issued, the clinic sends it to a dispensing pharmacy. The medicine is supplied in the prescribed format, with labels showing the patient's details, product and directions. Patients normally require follow-up appointments, especially during titration, when the dose or product may be adjusted to balance symptom control against side effects.

It is sensible to approach an assessment with a clear account of what has and has not worked. Describe symptoms, functional impact and treatment history accurately. A good consultation is not a test of how persuasively somebody can argue for a preferred strain or THC strength. It is an opportunity to determine whether a regulated treatment plan is safe and justified.

What does a prescription cost?

For most people, private care is the main route, so costs extend beyond the product itself. There may be an initial consultation fee, follow-up charges, a repeat-prescription fee, pharmacy dispensing costs and the monthly cost of medicine. Some clinics package elements of this differently, which can make advertised entry prices difficult to compare.

The total varies substantially according to the prescribed format, dose, frequency of reviews and pharmacy. Dried flower can be priced by gram, while oils are usually priced by bottle and cannabinoid concentration. A lower consultation fee does not necessarily mean a lower first-year cost if repeat fees or dispensing charges are higher.

Before committing, ask for the full expected cost over the first three to six months, including review appointments. Also ask what happens if the first product is ineffective or poorly tolerated, whether a prescription can be changed between appointments, and whether the clinic charges for administrative letters. A clinic should not promise that cannabis will work, guarantee eligibility or present prescribing as a consumer entitlement.

NHS prescribing is possible but remains exceptionally uncommon outside the licensed medicines and their approved indications. National guidance has generally taken a cautious position on unlicensed cannabis-based products because of limited evidence, cost-effectiveness concerns and clinical uncertainty. A private prescription does not create an NHS right to the same product.

Possession is lawful only within the prescription

A valid prescription can make possession of the prescribed medicine lawful, including products containing THC. That protection is personal and conditional. It does not legalise sharing medicine, selling it, carrying more than has been supplied, or using illicit cannabis alongside prescribed treatment.

Keep medication in its original pharmacy packaging and carry a copy of the prescription or clinic letter where practical. This is especially useful if travelling within the UK, dealing with an employer's medicine policy or speaking with police. It is evidence of lawful possession, not a guarantee that every situation will be resolved immediately or without questions.

The position becomes more complicated at the border. Countries set their own rules on controlled drugs, and a UK prescription does not automatically permit importation elsewhere. Patients should obtain written confirmation from the destination country's relevant authority before travelling, and check airline requirements. Taking prescribed cannabis abroad without the required permission can still lead to seizure or criminal consequences.

Driving, work and daily safety

The drug-driving rules are one of the most misunderstood parts of medical cannabis treatment. The UK has specified blood limits for several controlled drugs, including THC. A patient with a valid prescription may have a medical defence if they are taking the medicine as directed, but that defence does not apply where they are impaired or driving is unsafe.

The practical rule is straightforward: do not drive when affected. THC can impair reaction time, attention and judgement, particularly during early treatment, after a dose change, or when combined with alcohol, sedatives or poor sleep. A clinician may advise patients not to drive for a period while establishing how a product affects them. Employers in safety-critical roles may have separate fitness-for-work duties, even where treatment is lawfully prescribed.

Patients should tell the prescriber about driving, machinery, professional licences and workplace drug testing before treatment begins. A positive test may identify THC but cannot, on its own, explain whether a person was impaired at a particular time. That is why contemporaneous prescription documentation and honest clinical advice matter.

Questions worth asking before you book

The quality of a service is often clearest in the questions it is willing to answer. Ask whether the consultation is with a GMC-registered specialist, which pharmacy dispenses the prescription, how the clinic handles adverse effects, and what its follow-up policy is. Ask how it assesses mental health risk and whether it will communicate with your GP, with your consent.

It is also reasonable to ask about the exact product category proposed, the intended route of administration and why it is preferred. Smoking is not a prescribed route of administration. Where dried flower is prescribed, it is generally intended for vaporisation using an appropriate medical device, not combustion.

A legitimate medical cannabis pathway may still prove unsuitable, unaffordable or ineffective for an individual. That is not a failure by the patient. The most useful next step is a properly documented clinical conversation, with realistic expectations and safety given the same weight as symptom relief.